What diseases can Zafirlukast be used to treat

Zafirlukast is a triene receptor antagonist of a slow-reacting substance such as LTC4, LTD4 and LTE4, which is a potent oral peptide. It is competitively inhibited and has high selectivity. It can effectively prevent leukotriene peptides. Increased vascular permeability, tracheal edema, and infiltration of eosinophils.
Asthmatic patients are 10 times more sensitive to leukotriene D4 than normal people. A single oral dose of this drug makes asthma patients tolerant to inhaled LTD4 100 times, and has obvious protective effects in 12 and 24 hours. Bronchospasm caused by stimuli such as sulphur dioxide, exercise, and cold air, reducing early-onset and delayed inflammatory reactions caused by various causes such as pollen, cat dander, ragweed, and mixed antigens. For some patients, Zafirlukast also completely prevents asthma attacks caused by exercise and allergens. Zafirlukast can be used to maintain first-line treatment for asthma patients who are treated with beta agonists as needed but are not adequately controlled. For patients with clinical symptoms, Zafirlukast can relieve symptoms (reduce symptoms of diurnal asthma), improve lung function, reduce the amount of beta agonists and the incidence of asthma exacerbations.
Clinical studies have found that within 2 hours of taking the drug, the plasma concentration of the drug has not reached the peak, and it can produce a significant first dose effect on the basal bronchial movement tension. When Zavirlukast is used, the asthma symptoms are initially improved within 1 week, mostly in the first few days. appear. Oral Zafirlukast Tmax was 3h, administered twice daily (30-80mg, bid), it can be seen that the plasma accumulation of Zafirlukast was 2.9 times higher than the first dose, with an average of 1.45 and a median of 1.27. The PBP was 99% and the t1/2 was 10h. Zafirlukast is similar to healthy people in the pharmacokinetics of asthma young adults and adults. There is no gender difference in drug metabolism in Zafirlukast when administered by weight. With food, most patients (75%) have reduced bioavailability. Zafirlukast is fully metabolized and is mainly excreted in feces (89%) and urine (10%).